Organization · Venture Capital
Brain Trust Accelerator Fund, L.P.
Brain Trust Accelerator Fund, L.P. is a venture capital fund based in Burlingame, California, specializing in early-stage investments in brain-related diseases. The fund focuses on translational-stage opportunities that aim to improve diagnosis and treatment in this field.
Overview
What Brain Trust Accelerator Fund, L.P. does
What Brain Trust Accelerator Fund, L.P. is
Brain Trust Accelerator Fund, L.P. is a venture capital fund based in Burlingame, California, specializing in early-stage investments in brain-related diseases. The fund focuses on translational-stage opportunities that aim to improve diagnosis and treatment in this field.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2006
- Approximate age
- About 20 years
- Structured capabilities
- Funder
- Last reviewed
- April 26, 2026
Official channels
Find Brain Trust Accelerator Fund, L.P. elsewhere
Open the official website or a supported primary organization account.
Capability profile
Brain Trust Accelerator Fund, L.P. as a funder
Investment thesis
Brain Trust Accelerator Fund, L.P. focuses on moving brain-disease research into commercial clinical products, leveraging genomics and personalized medicine to address brain diseases earlier and more precisely.
Focus narrative
The fund specializes in translational stage investments targeting brain diseases, with a strategy aimed at developing impactful solutions for a large patient population. By concentrating on early-stage healthcare and life sciences, Brain Trust Accelerator Fund is positioned to support companies that are innovating in the fields of neurodegenerative diseases, CNS therapeutics, and neurotechnology.
Value beyond capital
Brain Trust Accelerator Fund adds value to its portfolio companies by leveraging its expertise in brain disease research and commercialization. The fund provides strategic guidance, access to philanthropic networks, and operational support to help companies navigate the complexities of bringing innovative therapies to market.
Focus and fit
- Stages
- Seed · Series A · Series B
- Sectors
- Healthcare · Biotech · Medical Devices
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- Chase Pharmaceuticals Corporation, Neurofluidics, Inc., Satoris, and Amnestix
Portfolio context
NeuroTherapia: A clinical-stage biotech developing oral small molecules for neuro-inflammatory CNS conditions, including Alzheimer's and Parkinson's diseases. Chase Therapeutics: Focused on therapeutics for Parkinson's and other neurodegenerative diseases. BrainScope Company, Inc.: Develops point-of-care assessment tools for brain injury and concussion. Neurofluidics, Inc.: Medical device company targeting serious neurological disorders. Satoris: Early-stage molecular diagnostics company for neurodegenerative diseases.
Common questions
What to know about Brain Trust Accelerator Fund, L.P.
Upseed classifies Brain Trust Accelerator Fund, L.P. under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.